Detalles de la búsqueda
1.
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Lancet
; 399(10336): 1695-1707, 2022 04 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35405085
2.
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Lancet Oncol
; 16(7): 787-94, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26028518
3.
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 14(2): 149-58, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23306100
4.
Multidisciplinary real-world management of metastatic castration-sensitive prostate cancer: A French national study (PROFILE study).
Fr J Urol
; 34(7-8): 102661, 2024 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38823482
5.
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
Eur Urol
; 85(3): 274-282, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37271630
6.
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.
Eur J Cancer
; 182: 66-76, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36746010
7.
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.
Clin Genitourin Cancer
; 21(5): 615.e1-615.e8, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37263910
8.
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.
Eur Urol
; 81(3): 234-240, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34789394
9.
REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study.
J Oncol
; 2022: 3449660, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35222642
10.
Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma.
Cells
; 11(1)2021 12 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35011579
11.
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Eur Urol
; 73(5): 696-703, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29074061
12.
First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.
Bull Cancer
; 104(6): 552-558, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28390646
13.
[We must respect the anti-SARS-CoV-2 vaccine schedule without delay in cancer patients under treatment]. / Nous devons respecter le schéma vaccinal anti-SARS-CoV-2 sans décalage chez les patients atteints de cancer sous traitement.
Bull Cancer
; 108(4): 341-342, 2021 Apr.
Artículo
en Francés
| MEDLINE | ID: mdl-33741139
14.
Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.
Int J Radiat Oncol Biol Phys
; 94(1): 85-92, 2016 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26576711
15.
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Eur Urol
; 68(2): 196-204, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25277272
16.
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).
Eur J Cancer
; 50(5): 953-62, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24424105
17.
Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.
J Clin Oncol
; 30(36): 4558-65, 2012 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-23109696
18.
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.
Eur J Cancer
; 48(2): 209-17, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22119204
19.
Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study.
Crit Rev Oncol Hematol
; 80(3): 466-73, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21565521
20.
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
J Clin Oncol
; 28(10): 1638-44, 2010 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20194850